Group | Week2 | Â | Â |
---|
 | 4 | 8 | 12 | Change wk 4–8 | Change wk 8–12 |
 | cm2 | cm2 | cm2 | cm2 | cm2 |
Placebo (n = 13) | 167.25 ± 87.96 | 144.13 ± 84.96* | 144.32 ± 89.18* | -23.12 ± 21.60 | 0.19 ± 18.11 |
CLA (n = 15) | 172.17 ± 82.93 | 162.37 ± 98.39 | 166.91 ± 94.46 | -9.79 ± 28.62 | 2.73 ± 14.99 |
- 1 Values are mean ± SD. *Significantly different from week 4, P < 0.05 (paired t-test).
- 2 Week 4 = end of placebo period for all subjects (run-in period); Week 8 = end of the CLA and placebo periods (supplementation period); Week 12 = end of placebo period for all subjects (run-out period).